MTVA Quote, Financials, Valuation and Earnings

Bioxytran has a net margin of -- compared to MetaVia's net margin of --. MetaVia's return on equity of -- beat Bioxytran's return on equity of --.

MetaVia has a consensus price target of $14.33, signalling upside risk potential of 2027.55%. On the other hand Bioxytran has an analysts' consensus of -- which suggests that it could fall by --. Given that MetaVia has higher upside potential than Bioxytran, analysts believe MetaVia is more attractive than Bioxytran.

MetaVia has a beta of 0.214, which suggesting that the stock is 78.621% less volatile than S&P 500. In comparison Bioxytran has a beta of 1.555, suggesting its more volatile than the S&P 500 by 55.542%.

MetaVia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bioxytran offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia pays -- of its earnings as a dividend. Bioxytran pays out -- of its earnings as a dividend.

MetaVia quarterly revenues are --, which are smaller than Bioxytran quarterly revenues of --. MetaVia's net income of -$3.7M is lower than Bioxytran's net income of -$1.4M. Notably, MetaVia's price-to-earnings ratio is -- while Bioxytran's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia is -- versus 53.82x for Bioxytran. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Path Holdings has a net margin of -- compared to MetaVia's net margin of --. MetaVia's return on equity of -- beat Bio-Path Holdings's return on equity of --.

MetaVia has a consensus price target of $14.33, signalling upside risk potential of 2027.55%. On the other hand Bio-Path Holdings has an analysts' consensus of $2.00 which suggests that it could grow by 1173.89%. Given that MetaVia has higher upside potential than Bio-Path Holdings, analysts believe MetaVia is more attractive than Bio-Path Holdings.

MetaVia has a beta of 0.214, which suggesting that the stock is 78.621% less volatile than S&P 500. In comparison Bio-Path Holdings has a beta of -0.032, suggesting its less volatile than the S&P 500 by 103.201%.

MetaVia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Path Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia pays -- of its earnings as a dividend. Bio-Path Holdings pays out -- of its earnings as a dividend.

MetaVia quarterly revenues are --, which are smaller than Bio-Path Holdings quarterly revenues of --. MetaVia's net income of -$3.7M is lower than Bio-Path Holdings's net income of -$2.9M. Notably, MetaVia's price-to-earnings ratio is -- while Bio-Path Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia is -- versus -- for Bio-Path Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Imunon has a net margin of -- compared to MetaVia's net margin of --. MetaVia's return on equity of -- beat Imunon's return on equity of --.

MetaVia has a consensus price target of $14.33, signalling upside risk potential of 2027.55%. On the other hand Imunon has an analysts' consensus of $10.25 which suggests that it could grow by 1977.84%. Given that MetaVia has higher upside potential than Imunon, analysts believe MetaVia is more attractive than Imunon.

MetaVia has a beta of 0.214, which suggesting that the stock is 78.621% less volatile than S&P 500. In comparison Imunon has a beta of 1.927, suggesting its more volatile than the S&P 500 by 92.726%.

MetaVia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia pays -- of its earnings as a dividend. Imunon pays out -- of its earnings as a dividend.

MetaVia quarterly revenues are --, which are smaller than Imunon quarterly revenues of --. MetaVia's net income of -$3.7M is higher than Imunon's net income of -$4.1M. Notably, MetaVia's price-to-earnings ratio is -- while Imunon's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia is -- versus 13.05x for Imunon. Usually stocks with elevated PS ratios are considered overvalued.

Tivic Health Systems has a net margin of -- compared to MetaVia's net margin of -2145.71%. MetaVia's return on equity of -- beat Tivic Health Systems's return on equity of -192.41%.

MetaVia has a consensus price target of $14.33, signalling upside risk potential of 2027.55%. On the other hand Tivic Health Systems has an analysts' consensus of -- which suggests that it could fall by --. Given that MetaVia has higher upside potential than Tivic Health Systems, analysts believe MetaVia is more attractive than Tivic Health Systems.

MetaVia has a beta of 0.214, which suggesting that the stock is 78.621% less volatile than S&P 500. In comparison Tivic Health Systems has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

MetaVia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tivic Health Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia pays -- of its earnings as a dividend. Tivic Health Systems pays out -- of its earnings as a dividend.

MetaVia quarterly revenues are --, which are smaller than Tivic Health Systems quarterly revenues of $70K. MetaVia's net income of -$3.7M is lower than Tivic Health Systems's net income of -$1.5M. Notably, MetaVia's price-to-earnings ratio is -- while Tivic Health Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia is -- versus 3.35x for Tivic Health Systems. Usually stocks with elevated PS ratios are considered overvalued.